A C Achhra1, A Phillips2, S Emery1, R D MacArthur3, H Furrer4, S De Wit5, M Losso6, M G Law1. 1. Kirby Institute, UNSW Australia, Sydney, NSW, Australia. 2. Research Department of Infection & Population Health, University College London, London, UK. 3. Wayne State University, Detroit, MI, USA. 4. Infectious Diseases, University Hospital, Bern, Switzerland. 5. Department of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium. 6. J.M. Ramos Mejía Hospital, Buenos Aires, Argentina.
Abstract
OBJECTIVES:Pre-antiretroviral therapy (ART) inflammation and coagulation activation predict clinical outcomes in HIV-positive individuals. We assessed whether pre-ART inflammatory marker levels predicted the CD4 count response to ART. METHODS: Analyses were based on data from the Strategic Management of Antiretroviral Therapy (SMART) trial, an international trial evaluating continuous vs. interrupted ART, and the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial, evaluating three first-line ART regimens with at least two drug classes. For this analysis, participants had to be ART-naïve or off ART at randomization and (re)starting ART and have C-reactive protein (CRP), interleukin-6 (IL-6) and D-dimer measured pre-ART. Using random effects linear models, we assessed the association between each of the biomarker levels, categorized as quartiles, and change in CD4 count from ART initiation to 24 months post-ART. Analyses adjusted for CD4 count at ART initiation (baseline), study arm, follow-up time and other known confounders. RESULTS: Overall, 1084 individuals [659 from SMART (26% ART naïve) and 425 from FIRST] met the eligibility criteria, providing 8264 CD4 count measurements. Seventy-five per cent of individuals were male with the mean age of 42 years. The median (interquartile range) baseline CD4 counts were 416 (350-530) and 100 (22-300) cells/μL in SMART and FIRST, respectively. All of the biomarkers were inversely associated with baseline CD4 count in FIRST but not in SMART. In adjusted models, there was no clear relationship between changing biomarker levels and mean change in CD4 count post-ART (P for trend: CRP, P = 0.97; IL-6, P = 0.25; and D-dimer, P = 0.29). CONCLUSIONS: Pre-ART inflammation and coagulation activation do not predict CD4 count response to ART and appear to influence the risk of clinical outcomes through other mechanisms than blunting long-term CD4 count gain.
RCT Entities:
OBJECTIVES: Pre-antiretroviral therapy (ART) inflammation and coagulation activation predict clinical outcomes in HIV-positive individuals. We assessed whether pre-ART inflammatory marker levels predicted the CD4 count response to ART. METHODS: Analyses were based on data from the Strategic Management of Antiretroviral Therapy (SMART) trial, an international trial evaluating continuous vs. interrupted ART, and the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial, evaluating three first-line ART regimens with at least two drug classes. For this analysis, participants had to be ART-naïve or off ART at randomization and (re)starting ART and have C-reactive protein (CRP), interleukin-6 (IL-6) and D-dimer measured pre-ART. Using random effects linear models, we assessed the association between each of the biomarker levels, categorized as quartiles, and change in CD4 count from ART initiation to 24 months post-ART. Analyses adjusted for CD4 count at ART initiation (baseline), study arm, follow-up time and other known confounders. RESULTS: Overall, 1084 individuals [659 from SMART (26% ART naïve) and 425 from FIRST] met the eligibility criteria, providing 8264 CD4 count measurements. Seventy-five per cent of individuals were male with the mean age of 42 years. The median (interquartile range) baseline CD4 counts were 416 (350-530) and 100 (22-300) cells/μL in SMART and FIRST, respectively. All of the biomarkers were inversely associated with baseline CD4 count in FIRST but not in SMART. In adjusted models, there was no clear relationship between changing biomarker levels and mean change in CD4 count post-ART (P for trend: CRP, P = 0.97; IL-6, P = 0.25; and D-dimer, P = 0.29). CONCLUSIONS: Pre-ART inflammation and coagulation activation do not predict CD4 count response to ART and appear to influence the risk of clinical outcomes through other mechanisms than blunting long-term CD4 count gain.
Authors: Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay Journal: J Infect Dis Date: 2010-06-15 Impact factor: 5.226
Authors: Rodger D MacArthur; Richard M Novak; Grace Peng; Li Chen; Ying Xiang; Katherine Huppler Hullsiek; Michael J Kozal; Mary van den Berg-Wolf; Christopher Henely; Barry Schmetter; Marjorie Dehlinger Journal: Lancet Date: 2006-12-16 Impact factor: 79.321
Authors: Amit C Achhra; Janaki Amin; Caroline Sabin; Haitao Chu; David Dunn; Lewis H Kuller; Joseph A Kovacs; David A Cooper; Sean Emery; Matthew G Law Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: Amit C Achhra; Janaki Amin; Matthew G Law; Sean Emery; Jan Gerstoft; Fred M Gordin; Michael J Vjecha; James D Neaton; David A Cooper Journal: AIDS Date: 2010-07-31 Impact factor: 4.177
Authors: Allan R Tenorio; Yu Zheng; Ronald J Bosch; Supriya Krishnan; Benigno Rodriguez; Peter W Hunt; Jill Plants; Arjun Seth; Cara C Wilson; Steven G Deeks; Michael M Lederman; Alan L Landay Journal: J Infect Dis Date: 2014-05-01 Impact factor: 5.226
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Lotty Ledwaba; Jorge A Tavel; Paul Khabo; Patrick Maja; Jing Qin; Phumele Sangweni; Xiao Liu; Dean Follmann; Julia A Metcalf; Susan Orsega; Beth Baseler; James D Neaton; H Clifford Lane Journal: PLoS One Date: 2012-03-20 Impact factor: 3.240
Authors: Bruno Bezerril Andrade; Katherine Huppler Hullsiek; David R Boulware; Adam Rupert; Martyn A French; Kiat Ruxrungtham; Marisa Luisa Montes; Huw Price; Pablo Barreiro; Jennifer Audsley; Alan Sher; Sharon R Lewin; Irini Sereti Journal: J Infect Dis Date: 2013-01-18 Impact factor: 5.226
Authors: Elizabeth Hamlyn; Sarah Fidler; Wolfgang Stöhr; David A Cooper; Giuseppe Tambussi; Mauro Schechter; Jose M Miro; Myra Mcclure; Jonathan Weber; Abdel Babiker; Kholoud Porter Journal: AIDS Date: 2014-03-27 Impact factor: 4.177
Authors: Héloïse M Delagreverie; Claire Bauduin; Nathalie De Castro; Beatriz Grinsztejn; Marc Chevrier; Fanélie Jouenne; Samia Mourah; Issa Kalidi; Jose Henrique Pilotto; Carlos Brites; Nemora Tregnago Barcellos; Ali Amara; Linda Wittkop; Jean-Michel Molina; Constance Delaugerre Journal: Open Forum Infect Dis Date: 2020-01-11 Impact factor: 3.835